A phase I, dose-escalation study of the Eg5-inhibitor EMD534085 in subjects with advanced solid tumors and lymphoma
Latest Information Update: 23 Apr 2015
At a glance
- Drugs EMD 534085 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck KGaA
Most Recent Events
- 21 Apr 2010 New trial record
- 17 Apr 2010 Results have been presented at the 101st Annual Meeting of the American Association for Cancer Research.